Search
Individuals with inside knowledge of the situation reveal that Merck & Co. has put a stop to its acquisition talks with the biotech firm Revolution Medicines (hereafter referred to as RevMed). Earlier on, Merck had placed a potential valuation of up to $30 billion on RevMed. Nevertheless, the two parties couldn't come to terms because of discrepancies in the price expectations, which resulted in a lull in the negotiation process.
That said, there remains a chance that the discussions might be rekindled. Moreover, RevMed could also draw the attention of other prospective buyers. Reports indicate that RevMed is set to unveil crucial test data for its drug candidates targeting pancreatic cancer and colorectal cancer in the first half of this year.
-
C114 Communication Network -
Communication Home
